Respiratory System Disorders Summary

Respiratory System Disorders

Congenital Disorders

  • Bronchial Atresia: Narrowing of the bronchus.
  • Hypoplasia of Lung: Smaller than normal lung size.
  • Bronchogenic Cysts: Cysts containing a significant amount of mucus.
  • Bronchopulmonary Sequestration: A portion of the lung that does not connect or communicate with the bronchial tree.
  • Kartagener's Syndrome (Immotile Cilia Syndrome): Defective cilia function.
  • Neonatal Respiratory Distress Syndrome (NRDS): Deficiency of surfactant, leading to alveolar collapse (atelectasis).
  • Cystic Fibrosis:
    • Caused by a CF gene mutation, resulting in the production of abnormally viscous mucus that cannot be effectively cleared from the lungs.
    • Leads to recurrent infections.
    • Can cause bronchiectasis and haemoptysis (coughing up blood).
    • May result in hyperinflation and pneumothorax.
    • Can progress to necrosis and scarring.
    • May lead to pulmonary hypertension and cor pulmonale.

Circulatory Disorders

  • Chronic Venous Congestion:
    • Decreased left ventricular (LV) output leads to rupture of alveolar capillaries.
    • Can cause haemorrhage, necrosis, and fibrosis.
    • Results in brown induration.
  • Pulmonary Oedema:
    • Caused by congestive heart failure, infections, gas inhalation, or radiation.
    • Leads to dyspnoea (shortness of breath) and hypostatic pneumonia.
  • Pulmonary Embolism:
    • In more than 80% of cases, originates from deep leg veins.
    • Causes dyspnoea, tachycardia, and shock.
    • Can result in infarction or fatal "saddle embolus."
  • Pulmonary Infarction:
    • Occurs in elderly or post-operative patients, or patients with heart failure.
    • Caused by thromboemboli.
    • Results in dyspnoea, scarring, or death.
  • Pulmonary Hypertension:
    • Primary hypertension is rare.
    • Secondary hypertension is due to lung or heart disease.
    • Causes dyspnoea and plexiform lesions.

Chronic Obstructive Pulmonary/Airways Disease (COPD/COAD)

  • A disease state characterized by persistent airflow limitation that is not fully reversible.
  • Symptoms include dyspnoea (shortness of breath), cough, and sputum production.
  • Emphysema:
    • Enlargement of alveolar spaces and loss of elastic recoil (distal to the terminal bronchiole).
    • Familial: Due to inherited defect in α\alpha-1-antiproteinase.
    • Acquired: Smoking leads to decreased α\alpha-1-antiproteinase, which cannot inactivate elastases released by neutrophils, resulting in the destruction of elastic tissue in alveolar walls.
  • Bronchiectasis:
    • Permanent dilatation of bronchi and bronchioles.
    • Results in recurrent cough and copious mucus production.
    • Due to chronic infections, TB/sarcoidosis, smoking/scarring, dust inhalations, tumors, cystic fibrosis, or immotile cilia syndrome.
  • Chronic Bronchitis & Bronchiolitis:
    • Mucous hypersecretion and inflammation of airways, leading to airway narrowing.
    • Due to smoking, dust/fume inhalations, or infections/inflammations.

Bronchial Asthma

  • Reversible bronchospasm causing wheezing and excess mucus, mediated by Type I hypersensitivity.
  • Extrinsic Asthma: Triggered by allergic or environmental factors.
  • Intrinsic Asthma: Triggered by exercise, stress, or psychogenic factors.
  • Sequelae: Mild disease, status asthmaticus, chronic asthma, COPD.

Infections & Inflammations

  • Lobar Pneumonia:
    • More common in young adults, often caused by S. pneumoniae.
    • Affects whole lung lobe(s).
    • Typically has an 8-day course and resolves.
  • Bronchopneumonia:
    • More common at age extremes, caused by different flora.
    • Results in patchy lesions and an irregular course with pus and fibrosis.
  • Tuberculosis:
    • Caseating granulomatous inflammation.
    • Airborne transmission of M. tuberculosis leads to tubercle formation.
  • Viral Infections:
    • Caused by influenza, rhinovirus, coxsackievirus, echovirus, SARS coronavirus, or CMV.
  • Fungal Infections:
    • Caused by Aspergillus spp, Cryptococcus spp, Candida albicans, or Pneumocystis jiroveci (formerly carinii).
  • Sarcoidosis:
    • Idiopathic, granulomatous inflammation, more common in women.
    • Associated with immune anomalies and a positive Kveim-Siltzback skin test.
  • Adult Respiratory Distress Syndrome (ARDS):
    • Diffuse alveolar damage due to septicaemia, major trauma, toxic smoke/fume inhalation, amniotic fluid embolism, DIC, radiation injury, or chemotherapy.
    • Has a high mortality rate (70% in the acute phase).

Pneumoconioses

  • Organic:
    • Byssinosis (cotton protein).
    • Bagassosis (sugar cane refuse).
    • Farmers’ lung (mouldy hay).
    • Suberosis (cork dust).
  • Inorganic:
    • Anthracosis: Carbon; Commonly found in cigarette smokers; Mostly harmless.
    • Silicosis: Silica; Quarry workers, stone masons; Predisposes to TB, COPD, and right heart (RH) problems.
    • Silicoanthracosis: Carbon & silica; Coal workers; Results similar to silicosis.
    • Berylliosis: Beryllium; Miners, electronics industry; Can lead to granulomas and COPD.
    • Silicosiderosis: Silica & iron; Miners, iron ore workers; Predisposes to TB, lung malignancy.
    • Asbestosis: Asbestos; Miners, building/automotive industries; Most harmful; Leads to asbestosis, COPD, and mesothelioma of pleura.

Tumours

  • Mesothelioma of the Pleura:
    • Exposure to asbestos.
    • Highly malignant; death usually within 10 months of diagnosis.
  • Carcinoma of Bronchus:
    • Due to smoking, X-rays, γ\gamma-rays, Radon gas, asbestosis, silicosiderosis, or mining of Ni, Cr.
    • Can be central (~55%), peripheral (~40%), or diffuse (~5%).
    • May cause Pancoast/Horner’s syndromes.
    • Diagnosis: Chest X-ray, bronchoscopy & biopsy, needle biopsy, sputum cytology, MRI/CT/bone & brain scans.
    • Treatment: Surgery, radiotherapy, chemotherapy, or combined treatments.
    • Morphology:
      • Squamous cell carcinoma (~50%).
      • Small cell anaplastic ca. (“oat cell” ~20%, worst prognosis).
      • Large cell anaplastic ca. (~10%).
      • Adenocarcinoma (~15%).
      • Alveolar cell carcinoma (~5%, best prognosis).
    • Staging: TNM (Tumour TX, TIS, T1, T2, T3; Lymph node N0, N1, N2; Metastasis M0, M1); Average 5-year survival <10%.
  • Secondary Tumours: Breast, bone, skin, and kidney tumors commonly metastasize to the lung.